In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

Yet only “Gray Tree” has scale-invariant branch diameters. When Mondrian removes the scale invariance in “Blooming Apple Tree ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

M Investment Round Highlights D-Fend’s Global Leadership in Counter-Drone Technology Across Industries With drones becoming ...

Walmart’s Presidents Day sale has hundreds of deals on brands like Apple, Lego, Shark, Dyson, Michael Kors, Kate Spade, and ...

Moderna beat analysts’ revenue expectations by 48.8% last quarter, reporting revenues of $1.86 billion, up 1.7% year on year. It was an exceptional quarter for the company, with a solid beat of ...

Using the 2 Stage Free Cash Flow to Equity, Emeco Holdings fair value estimate is AU$1.90. Emeco Holdings is estimated to be 49% undervalued based on current share p ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

SpotDraft, a contract lifecycle management (CLM) platform, has raised $54 million in its Series B funding round led by Vertex ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

In this post, I explain how a newly introduced bias--likelihood neglect bias--can prevent us from forming accurate judgments about the world.

Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.